Contrasting GlobeImmune (OTCMKTS:GBIM) and Carisma Therapeutics (NASDAQ:CARM)

Carisma Therapeutics (NASDAQ:CARM) and GlobeImmune (OTCMKTS:GBIM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Earnings & Valuation

This table compares Carisma Therapeutics and GlobeImmune’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$20.71 million	2.15	-$86.88 million	($2.00)	-0.54
GlobeImmune	N/A	N/A	N/A	N/A	N/A

GlobeImmune has lower revenue, but higher earnings than Carisma Therapeutics.

Analyst Ratings

This is a summary of current recommendations and price targets for Carisma Therapeutics and GlobeImmune, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	0	0	3	0	3.00
GlobeImmune	0	0	0	0	N/A

Carisma Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 647.66%.

Profitability

This table compares Carisma Therapeutics and GlobeImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-538.81%	-215.95%	-80.58%
GlobeImmune	N/A	N/A	N/A

Risk and Volatility

Carisma Therapeutics has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, GlobeImmune has a beta of -193.85, meaning that its stock price is 19,485% less volatile than the S&P 500.

Institutional & Insider Ownership

44.3% of Carisma Therapeutics shares are held by institutional investors. 17.0% of Carisma Therapeutics shares are held by company insiders. Comparatively, 23.5% of GlobeImmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

About Carisma Therapeutics

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

About GlobeImmune

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of ImmunityBio, Inc.